Takeda presented promising data on its ulcerative colitis and Crohn’s disease drug Entyvio at the World Congress of Gastroenterology at ACG2017, Oct. 13 to Oct. 18 in Orlando, Fla. The data suggests ...
This clinical brief was sponsored by Takeda Pharmaceuticals U.S.A., Inc,. This information is exclusively for Payer Formulary Committees or other similar entities (groups of individuals that evaluate ...
ORLANDO -- Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis previously untreated with a biologic, but the integrin receptor ...
Entyvio is indicated for the treatment of Ulcerative Colitis and Crohn’s disease REYKJAVIK, Iceland, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Alvotech, a global biotech company specialized in the ...
Exton, Pennsylvania, March 22, 2024 (GLOBE NEWSWIRE) -- The end of 2023 introduced several new treatment options for patients suffering from ulcerative colitis (UC). Among them is Eli Lilly’s Omvoh ...
Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. This is an exciting time to think about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results